Scott L. Burrows - 28 Feb 2023 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Role
Chief Financial Officer
Signature
/s/ Scott L. Burrows
Issuer symbol
ARQT
Transactions as of
28 Feb 2023
Net transactions value
-$29,421
Form type
4
Filing time
02 Mar 2023, 18:05:53 UTC
Previous filing
20 Sep 2022
Next filing
06 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARQT Common Stock Sale $6,725 -416 -1% $16.17 39,840 28 Feb 2023 Direct F1, F2
transaction ARQT Common Stock Sale $22,399 -1,416 -3.6% $15.82 38,424 02 Mar 2023 Direct F1, F3
transaction ARQT Common Stock Sale $297 -18 -0.05% $16.52 38,406 02 Mar 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
F2 The transaction was executed in multiple trades in prices ranging from $15.990 to $16.320, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 The transaction was executed in multiple trades in prices ranging from $15.470 to $16.460, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.